Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 6/20 | 0.65 |
| ▸ | CSNK1E | P49674 | 4/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.65 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.65 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.65 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.65 |
| ▸ | BRAF | P15056 | 7/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.58 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.58 |
| ▸ | CIT | O14578 | 2/20 | 0.58 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.58 |
| ▸ | STK10 | O94804 | 2/20 | 0.58 |
| ▸ | ABL1 | P00519 | 2/20 | 0.58 |
| ▸ | RAF1 | P04049 | 2/20 | 0.58 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.58 |
| ▸ | JAK1 | P23458 | 2/20 | 0.58 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.58 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6077523 | 1.00 | CSNK1D (0.65) | CSNK1DCSNK1EMAPK14MAPK13MAPK12 | |
| SCHEMBL17088198 | 0.87 | BRAF (0.60) | CSNK1DCSNK1EMAPK14MAPK13MAPK12 | |
| SCHEMBL17088200 | 0.86 | MEN1 (0.62) | CSNK1DCSNK1EMAPK14MAPK13MAPK12 | |
| SCHEMBL5452499 | 0.85 | CSNK1D (0.60) | CSNK1DCSNK1EMAPK14MAPK13MAPK12 | |
| SCHEMBL27716525 | 0.85 | PTGIR (0.58) | CSNK1DCSNK1EMAPK14MAPK13MAPK12 | |
| SCHEMBL14519366 | 0.85 | PTGIR (0.58) | CSNK1DCSNK1EMAPK14MAPK13MAPK12 | |
| SCHEMBL14411548 | 0.85 | MAPK14 (0.57) | CSNK1DCSNK1EMAPK14MAPK13MAPK12 | |
| SCHEMBL5257891 | 0.84 | CSNK1D (0.56) | CSNK1DCSNK1EMAPK14MAPK13MAPK12 | |
| SCHEMBL1646293 | 0.84 | PTGIR (0.62) | CSNK1DCSNK1EMAPK14MAPK13MAPK12 | |
| SCHEMBL5444414 | 0.84 | MAP4K4 (0.67) | CSNK1DCSNK1EMAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176433-A1 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | PHARMACIA CORPORATION | 2004-09-09 | — | — | US | claimed |
| US-6423713-B1 | Substituted pyrazoles as p38 kinase inhibitors | G. D. SEARLE & COMPANY | 2002-07-23 | — | — | US | claimed |
| CN-1264377-A | Substituted pyrazoles as P38 kinase inhabitors | SEARLE & CO (US) | 2000-08-23 | — | — | CN | claimed |
| EP-1000055-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1998052940-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | claimed |
| US-7964534-B2 | Nuclear magnetic resonance assembly of chemical entities using advanced antenna probes | TRIAD LIQUIDATING COMPANY, LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964534-B2 | Nuclear magnetic resonance assembly of chemical entities using advanced antenna probes | TRIAD LIQUIDATING COMPANY, LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964534-B2 | Nuclear magnetic resonance assembly of chemical entities using advanced antenna probes | TRIAD LIQUIDATING COMPANY, LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-20110118148-A1 | NUCLEAR MAGNETIC RESONANCE ASSEMBLY OF CHEMICAL ENTITIES USING ADVANCED ANTENNA PROBES | TRIAD LIQUIDATING COMPANY, LLC | 2011-05-19 | — | — | US | disclosed |
| US-20110118148-A1 | NUCLEAR MAGNETIC RESONANCE ASSEMBLY OF CHEMICAL ENTITIES USING ADVANCED ANTENNA PROBES | TRIAD LIQUIDATING COMPANY, LLC | 2011-05-19 | — | — | US | disclosed |
| US-20110118148-A1 | NUCLEAR MAGNETIC RESONANCE ASSEMBLY OF CHEMICAL ENTITIES USING ADVANCED ANTENNA PROBES | TRIAD LIQUIDATING COMPANY, LLC | 2011-05-19 | — | — | US | disclosed |
| EP-1500657-B1 | Substituted pyrazoles as P38 kinase inhibitors | SEARLE LLC (US) | 2007-09-19 | — | — | EP | disclosed |
| US-6423713-B1 | Substituted pyrazoles as p38 kinase inhibitors | G. D. SEARLE & COMPANY | 2002-07-23 | — | — | US | disclosed |
| CN-1342157-A | Substituted pyrazoles ASP38 kinase inhibitors | SEARLE & CO (US) | 2002-03-27 | — | — | CN | disclosed |
| EP-1144403-A1 | SUBSTITUED PYRAZOLES AS P38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 2001-10-17 | — | — | EP | disclosed |
| CN-1273603-A | Attenuated respiratory syncytial virus | AMERICAN CYANAMID CO (US) | 2000-11-15 | — | — | CN | disclosed |
| CN-1264377-A | Substituted pyrazoles as P38 kinase inhabitors | SEARLE & CO (US) | 2000-08-23 | — | — | CN | disclosed |
| WO-2000031063-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-06-02 | — | — | WO | disclosed |
| EP-1000055-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1998052940-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118148-A1 | NUCLEAR MAGNETIC RESONANCE ASSEMBLY OF CHEMICAL ENTITIES USING ADVANCED ANTENNA PROBES | AURKAIP1, MRPS27, ATRIP | CSNK1D 4712/4885CSNK1E 4132/4885MAPK14 3240/4885 |
| US-20040176433-A1 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | MAPK1, IL1R1, TNF | CSNK1D 254/4885CSNK1E 907/4885MAPK14 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.